QPS Austria is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn QPS into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of AD, PD, HD and other neurodegenerative diseases.

 

QPS Austria is known for

  • Customers contentedness being our absolute priority
  • High quality studies on GLP level
  • Every study being custom-built
  • Clients timeline being QPS´ timeline
  • Being scientifically up to date
  • Being GLP certified and AAALAC accredited